Find all School-related info fast with the new School-Specific MBA Forum

It is currently 01 Dec 2015, 01:37
GMAT Club Tests


GMAT Club Daily Prep

Thank you for using the timer - this advanced tool can estimate your performance and suggest more practice questions. We have subscribed you to Daily Prep Questions via email.

for You

we will pick new questions that match your level based on your Timer History

Your Progress

every week, we’ll send you an estimated GMAT score based on your performance


we will pick new questions that match your level based on your Timer History

Not interested in getting valuable practice questions and articles delivered to your email? No problem, unsubscribe here.

Events & Promotions

Events & Promotions in June
Open Detailed Calendar

  Question banks Downloads My Bookmarks Reviews Important topics  
Author Message
User avatar
Joined: 16 Oct 2003
Posts: 1813
Followers: 4

Kudos [?]: 74 [0], given: 0  [#permalink] New post 30 Aug 2004, 19:54

IDSA has investigated the decline in new antibiotic R&D for
more than a year, interviewing stakeholders from all
sectors. Society leaders have met with officials from the
Food and Drug Administration (FDA), the National Institute
of Allergy and Infectious Diseases (NIAID), the Centers for
Disease Control and Prevention (CDC), congressional
members and staff, executives from leading
pharmaceutical and biotechnology companies,
representatives from public-private partnerships that are
focused on infectious diseases-related product
development, patients, and other stakeholders. Each
stakeholder has an important role in furthering future
antibiotic discovery and development and limiting the
impact of antibiotic resistance. However, based upon past
successes, the pharmaceutical and biotechnology industries
are clearly best situated to take the lead in developing the
new antibiotics needed to treat bacterial diseases. As such,
industry action must become the central focus of an
innovative federal public health effort designed to
stimulate antibiotic R&D.

IDSA’s investigation has revealed that the incentives most
likely to spur R&D within major pharmaceutical companies
include those that provide financial benefits prior to a
drug’s approval (e.g., tax credits for R&D), commence at
the time of approval (e.g., wild-card patent extension),
reduce the costs of clinical trials (e.g., FDA flexibility
concerning the evidence necessary to demonstrate safety
and efficacy; NIAID-sponsored research to develop rapid
diagnostics tests, etc.), and reduce companies’ risks (e.g.,
liability protections). R&D at smaller biotechnology
companies also could be stimulated through statutory and
administrative changes. Finally, new funding for critical
federal public health programs, and public and private
research efforts, would help to ensure progress as well as
limit the public health impact of antibiotic resistance.
User avatar
Joined: 13 Nov 2003
Posts: 968
Location: Florida
Followers: 1

Kudos [?]: 57 [0], given: 0

 [#permalink] New post 31 Aug 2004, 16:20
hale bhai!

you guys can try this link, if you like non-fiction reading.

I love this site. it is just too engrossing
User avatar
Joined: 16 Oct 2003
Posts: 1813
Followers: 4

Kudos [?]: 74 [0], given: 0

 [#permalink] New post 01 Sep 2004, 07:39
Thanks dj, will surely run by it often.
  [#permalink] 01 Sep 2004, 07:39
Display posts from previous: Sort by

  Question banks Downloads My Bookmarks Reviews Important topics  

GMAT Club MBA Forum Home| About| Privacy Policy| Terms and Conditions| GMAT Club Rules| Contact| Sitemap

Powered by phpBB © phpBB Group and phpBB SEO

Kindly note that the GMAT® test is a registered trademark of the Graduate Management Admission Council®, and this site has neither been reviewed nor endorsed by GMAC®.